PixelLabs
PixelLabs Raises $40M Series B to Transform Biotech
Quick Facts
PixelLabs Raises $40M Series B in Latest Funding Round
PixelLabs has successfully closed a $40M Series B funding round, marking a significant milestone in the company's growth trajectory. The round was led by General Catalyst, with participation from Sequoia Capital.
Company Overview
Founded in 2025 and headquartered in Washington, DC, PixelLabs has established itself in the Biotech space. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses
With a current valuation of $350M, the company has demonstrated strong market traction and investor confidence.
Investment Details
- Amount Raised: $40M Series B
- Valuation: $350M
- Lead Investor: General Catalyst
Future Outlook
As PixelLabs moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.
Key Investors
About the Author
Related Company Reports
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza